|
| Press Releases |
|
 |
|
| Thursday, August 29, 2024 |
|
|
康希諾生物2024上半年業績亮眼：流腦疫苗引領增長，加快合作與國際化步伐 |
| 康希諾生物今日披露了2024年上半年業績報告，營收達到3.03億元，其中流腦結合疫苗家族再度展現强勁增長動力，尤其是ACYW135群腦膜炎球菌多糖結合疫苗（CRM197載體）（以下簡稱“MCV4”）曼海欣®作爲亞洲首個腦膜炎球菌四價結合疫苗産品，不僅填補了市場空白，更爲我國嬰幼兒流腦疾病預防樹立了新標杆。 more info >> |
|
|
康希诺生物2024上半年业绩亮眼：流脑疫苗引领增长，加快合作与国际化步伐 |
| 康希诺生物今日披露了2024年上半年业绩报告，营收达到3.03亿元，其中流脑结合疫苗家族再度展现强劲增长动力，尤其是ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）（以下简称“MCV4”）曼海欣®作为亚洲首个脑膜炎球菌四价结合疫苗产品，不仅填补了市场空白，更为我国婴幼儿流脑疾病预防树立了新标杆。 more info >> |
|
| Friday, April 26, 2024 |
|
|
CanSinoBIO CSO Shares Latest Results of the Company's Globally Innovative Pneumococcal Vaccine |
| On April 20, the 2024 National Vaccines and Health Conference organized by the Chinese Preventive Medicine Association (CPMA) and the Chinese Center for Disease Control and Prevention (China CDC) took place in the Xiong'an New Area of Hebei Province. more info >> |
|
| Wednesday, March 27, 2024 |
|
|
来自康希诺生物的亚洲首个流脑结合疫苗商业化取得巨大突破 |
| 2023年，康希诺流脑结合疫苗实现营业收入约56,172.4万元，较去年同期增长约266.39%，增长趋势明显。 more info >> |
|
|
來自康希諾生物的亞洲首個流腦結合疫苗商業化取得巨大突破 |
| 2023年，康希諾流腦結合疫苗實現營業收入約56,172.4萬元，較去年同期增長約266.39%，增長趨勢明顯。 more info >> |
|
|
The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough |
| In 2023, CanSinoBIO's meningococcal conjugate vaccine achieved revenue approximately RMB561.72 million, representing a year-on-year increase of approximately 266.39% compared to last year. The growth trend is evident. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
FWD Group survey reveals over 70 per cent of Asia's middle-class feel anxiety about financial wellbeing, preventing longer-term planning
Feb 4, 2026 9:06 JST
|
|
|
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
Feb 4, 2026 08:04 HKT/SGT
|
|
|
Casa Minerals Inc. Announces Closing of First Tranche of Private Placement
Feb 4, 2026 07:59 HKT/SGT
|
|
|
先導智能赴港招股：新能源裝備龍頭 開啟全球增長新篇章
Feb 3, 2026 19:20 HKT/SGT
|
|
|
先导智能赴港招股：新能源装备龙头 开启全球增长新篇章
Feb 3, 2026 19:20 HKT/SGT
|
|
|
卡奧斯遞表港交所：工業數智化龍頭 為製造業培育新質生產力注入強勁動能
Feb 3, 2026 19:20 HKT/SGT
|
|
|
DENSO Announces Third Quarter Financial Results
Feb 3, 2026 19:36 JST
|
|
|
FWD Group survey reveals over 70 per cent of Asia's middle-class feel anxiety about financial wellbeing, preventing longer-term planning
Feb 3, 2026 15:13: JST
|
|
|
富士通、パブリックコメント業務に大規模言語モデル「Takane」を活用し、中央省庁で業務効率化の実証実験を実施
Feb 3, 2026 14:30: JST
|
|
|
富衛集團調查顯示逾七成亞洲中產對財務健康感到焦慮 阻礙長遠規劃
Feb 3, 2026 14:13 HKT/SGT
|
|
|
卡奧斯衝擊港股「AI+工業互聯網」第一股 數智生態賦能新型工業化
Feb 3, 2026 13:14 HKT/SGT
|
|
|
港股「釣魚第一股」樂欣戶外（2720.HK）啟動招股 將於2月10日正式上市
Feb 3, 2026 10:58 HKT/SGT
|
|
|
Fujitsu's Takane LLM successfully piloted in central government agency to streamline public comment operations
Feb 3, 2026 11:14 JST
|
|
|
EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions
Feb 3, 2026 10:00 JST
|
|
|
上實集團攜手Azzurra Capital合作落地 共啟亞洲綠色科技投資
Feb 3, 2026 08:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
